QI
ELOS

QS Investors’s Syneron Medical Ltd ELOS Stock Holding History

QS Investors’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-33,713
Closed -$369K – 2021
2017
Q2 		$369K Sell
33,713
-20,261
-38% -$222K ﹤0.01% 1015
2017
Q1 		$569K Buy
53,974
+688
+1% +$6.65K ﹤0.01% 926
2016
Q4 		$448K Hold
53,286
– – ﹤0.01% 906
2016
Q3 		$382K Sell
53,286
-11,400
-18% -$79.3K ﹤0.01% 950
2016
Q2 		$497K Hold
64,686
– – ﹤0.01% 903
2016
Q1 		$473K Hold
64,686
– – ﹤0.01% 908
2015
Q4 		$499K Hold
64,686
– – ﹤0.01% 898
2015
Q3 		$463K Sell
64,686
-8,025
-11% -$77.1K ﹤0.01% 897
2015
Q2 		$772K Buy
72,711
+35,211
+94% +$412K 0.01% 807
2015
Q1 		$464K Buy
+37,500
New +$415K 0.01% 892

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

QS Investors's ELOS Position: Q3 2017 in Review

QS Investors sold out of Syneron Medical Ltd (ELOS) in Q3 2017, closing a stake of 33,713 shares — an estimated $369K sold.

QS Investors first reported a position in ELOS in Q1 2015 and held it in 10 quarters. The position peaked at $772K in Q2 2015. 4 funds tracked by Wall St. Rank hold ELOS as of Q3 2017.

  • QS Investors reported no remaining Syneron Medical Ltd position as of Q3 2017 after selling out during the quarter.
  • QS Investors sold 33,713 Syneron Medical Ltd shares in Q3 2017, an estimated $369K.
  • QS Investors first reported a position in Syneron Medical Ltd in Q1 2015 and held it in 10 quarters.
  • QS Investors's Syneron Medical Ltd position peaked at $772K in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2017.

Based on QS Investors's 13F filing for Q3 2017, filed 14 Nov 2017.